comparemela.com

Latest Breaking News On - Prnewswire bausch health companies inc - Page 14 : comparemela.com

Bausch Health Announces CFO Succession Plan

Bausch Health Announces CFO Succession Plan News provided by Share this article Herendeen Will Remain at Bausch Health as Advisor to the Chairman and CEO LAVAL, Quebec, March 11, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) today announced that Chief Financial Officer (CFO) Paul S. Herendeen will be appointed to the newly created role of Advisor to the chairman and chief executive officer (CEO) of Bausch Health, effective June 1, 2021. Mr. Herendeen will be succeeded as CFO by Sam Eldessouky, senior vice president, controller and chief accounting officer of Bausch Health. Mr. Herendeen will remain an executive vice president (EVP) and Section 16 officer of Bausch Health.

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

Bausch Health Announces Agreement With Carl C Icahn

Icahn to Support All Bausch Health Nominees for Election at 2021 Annual Meeting LAVAL, QB, Feb. 24, 2021 /PRNewswire/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health or the Company ) is pleased to announce that it will expand its Board of Directors (the Board ) to add two designees to the Board from Carl C. Icahn and affiliated entities (the Icahn Group ). The Company has entered into a director nomination and appointment agreement (the Agreement ) with the Icahn Group, pursuant to which Brett Icahn and Steven Miller will be appointed to the Board as new independent directors, effective in mid-March 2021, with each to serve a term expiring at the Company s 2021 Annual Meeting. The Company has also agreed to include Messrs. B. Icahn and Miller on its slate of nominees for election at the Company s 2021 Annual Meeting, which will be held on April 27, 2021, and the Icahn Group, which beneficially owns approximately 7.83% of the Company s outstanding common stock, h

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.